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SUMMARY. The current preferred treatment for patients
with hepatitis C virus (HCV) is combination therapy
consisting of pegylated interferon alfa and ribavirin (RBV)
for 24–48 weeks. Although this approach appears to be
highly effective for patients with HCV genotypes 2 or 3,
who have a sustained virological response (SVR) of
approximately 80%, the treatment algorithm is less effec-
tive for patients with HCV genotype 1, as these patients
have SVR rates of just 40–50%. In order to improve
treatment outcomes, this article explores potential ap-
proaches for the optimization of treatment for patients with
HCV genotype 1: considering shorter treatment periods for
patients with a rapid virological response (RVR), increasing
treatment periods for slow responders, and increasing RBV
dose are all suggestions. Results from clinical trials suggest
that approximately 20% of the HCV genotype 1-infected
population are slow responders, and around 15% of all
HCV genotype-1 infected patients could beneﬁt from a
shorter treatment duration without compromising the SVR
rate. Interest has also focused on whether treatment
duration could be individualized in some patients with
genotype 2 and 3 infection. Here all the ﬁndings from re-
cent studies are translated into practical advice, to help
practitioners make evidence-based treatment decisions in
everyday clinical practice. Although there are areas where
currently available data do not provide conclusive evidence
to suggest amending treatment approaches, there is clearly
potential for individualized treatment in all aspects of
hepatitis treatment in the future.
Keywords: hepatitis C, pegylated interferon alfa, ribavirin,
treatment, virological response.
INTRODUCTION
Current treatment algorithms result in rates of sustained
virological response (SVR) of 80% in patients infected with
HCV genotypes 2 or 3, suggesting that some of the primary
challenges in the management of chronic hepatitis C (CHC)
have now been resolved. However, in patients infected with
HCV genotype 1, the standard combination treatment of
48 weeks of pegylated interferon alfa (peginterferon) and
ribavirin (RBV) results in SVR rates of only 40–50% [1,2],
with higher rates following 48 weeks rather than with
24 weeks of treatment (51% vs 41%, respectively) [3].
Emerging data suggest that treatment duration may be
shortened or lengthened depending on baseline viral load
and virological response at week 4 and⁄or week 12. This
paper considers these results and their implications for
treatment optimization and suggests how this latest research
can be translated into everyday clinical practice.
ISSUES UNDER CONSIDERATION
Principal considerations for treatment of CHC include dose
and duration of antiviral therapy (along with related costs),
quantiﬁcation of baseline HCV RNA levels, the deﬁnition of
response during the early stages and at the end of treatment,
as well as the duration of the post-treatment follow-up
Abbreviations: ALT, alanine-aminotransferase; cEVR, complete early
virologic response; CHC, chronic hepatitis C; EOT, end-of-treatment;
HCV, hepatitis C virus; LVL, low-viral load; pEVR, partial early vir-
ologic response; RBV, ribavirin; RVR, rapid virological response;
SVR, sustained virological response.
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uncertainty that have also to be taken into consideration,
such as the variation in baseline viral load, monitoring time
points and the time window within which monitoring
needs to take place.
Current treatment algorithm for treatment of patients with
HCV
Current treatment recommendations for patients chroni-
cally infected with HCV are shown in Fig. 1 [4–6]. Brieﬂy,
patients with genotype 2 or 3 infection are more responsive
to the current standard of care of peginterferon plus RBV
than those with genotype 1 or genotype 4 infection. The
rates of SVR for genotype 2 or 3 infection are similar in
patients treated for 24 or 48 weeks; thus, for these patients
24-week treatment is generally considered appropriate. For
patients infected with HCV genotype 1, the recommended
treatment duration is 48 weeks of peginterferon with RBV.
While standard doses for peginterferon alfa-2a (180 lg, qw)
and peginterferon alfa-2b (1.5 lg⁄kg, qw) are well estab-
lished, different recommendations exist for RBV dose
according to HCV genotype and type of peginterferon [7,8].
It appears that lower doses of RBV are required for treat-
ment of patients infected with HCV genotype 2 or 3 than
for genotypes 1 or 4 [9,10]. For the standard duration of
treatment of HCV genotype 1 and 4 infection, weight-based
RBV doses of 800–1200 mg, qd, or up to 1400 mg for
patients above 105 kg, are recommended, while no addi-
tional beneﬁt of RBV doses higher than 800 mg in HCV
genotype 2 and 3 infection was observed in several studies
[3,11]. Available data for patients infected with genotype 5
or 6 are limited; therefore, combination treatment with
1000⁄1200 mg, qd, RBV for 48 weeks is currently rec-
ommended.
Determination and monitoring of viral load
The decision on whether to continue or stop therapy should
primarily be based on the level of HCV RNA during treat-
ment. Therefore, it is necessary to measure viral load accu-
rately. Important aspects to consider in this respect are the
natural ﬂuctuations in viral load during infection, as well as
intra-assay (within an individual test) and inter-assay
(between different tests) variability. Currently available
commercial assays vary considerably in their dynamic ran-
ges of quantiﬁcation (Table 1). Despite the introduction of
international units per mL (IU⁄mL) for reporting viral load,
discrepancies may occur when patients are monitored using
different types of assay [14–19]. For example, rules for early
discontinuation at week 12 and 24, as well as rules for
determination of treatment duration [baseline viral load,
RVR, complete early viral response (cEVR)], were established
mainly with standard RT-PCR based assays, which have
since been replaced by real-time PCR-based assays with
higher sensitivity and broader dynamic range of linear HCV
RNA quantiﬁcation. The differences between commercial
HCV RNA assays have been well documented in several
studies [15–19], with the majority of studies showing an
intra-assay variability of approx. 0.2 log. Generally, com-
parisons between Amplicor Monitor and CAP⁄CTM yielded
comparable results (±0.2 log), whereas comparisons be-
tween bDNA and Abbott real-time HCV on the one hand and
CAP⁄CTM on the other showed a difference of 0.5–0.7 log.
Additionally, HCV RNA viral load decline assessed during
antiviral therapy can give different results, regardless of the
use of IUs. False-positive and false-negative results, as well as
variations in the HCV RNA level of up to 2 log10 IU, have
been observed, which may well have an impact on the
management of patients, particularly if treatment decisions
are made using a single HCV RNA assessment [15,16,19].
Fig. 1 Overview of current treatment guidelines (based on references [4–6,12,13]).
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76 S. Zeuzem et al.Practitioners should be careful not to attach undue clinical
signiﬁcance to small changes (<0.5 log10) in serum HCV
RNA level. The clinical relevance of serial HCV viral level
measurements in a patient is dependent on continuous use
of the speciﬁc quantitative assay employed in the initial
determination of the viral level. This may imply repeated
testing in some cases; but these extra costs may be justiﬁed if
they affect treatment management decisions.
GENOTYPE 1
Week 12 stopping rule for patients with HCV genotype 1
The current week 12 stopping rule recommends that
patients without a ‡2 log10 drop in viral load compared to
baseline (between 19% and 29% of patients with genotype 1
infection) discontinue therapy since the likelihood of
achieving SVR with continued treatment is small; the neg-
ative predictive value is almost 100% [21,22]. Over-treat-
ment of patients who have an extremely low chance of
achieving SVR is thus avoided and valuable resources can be
reserved for patients with a higher chance of treatment
success [23]. Week 12 monitoring should be carried out as
close as possible to the week 12 time point, ideally ±5 days,
using a test with high sensitivity and wide dynamic range.
Whether the 2 log10 drop represents the most accurate cut-
off level for the decision on treatment termination or pro-
ceeding remains to be determined in prospective clinical
studies. It is likely that with greater use of more sensitive
assays with a broader range of linear quantiﬁcation (e.g.
real-time PCR assays), this parameter may be re-
ﬁned⁄adjusted in the near future. It may also be the case
that new drugs currently in development will require dif-
ferent threshold levels and⁄or stopping rules based on their
different modes of action, although this remains to be seen.
Assessment at week 24 in patients with HCV genotype 1
If, at week 12, HCV RNA remains detectable but the viral
load has dropped by at least 2 log10 (i.e. 100-fold) from
baseline, treatment should be continued for the full 48-week
course. However, if the patient remains HCV RNA positive at
week 24, it is unlikely that an SVR will be achieved (negative
predictive value 98–100%), [2,21,24], and, unless the
patient is considered at high risk due to rapidly progressing
ﬁbrosis, treatment termination at week 24 can be consid-
ered. Studies are ongoing to determine whether patients may
derive some beneﬁt from treatment with peginterferon
monotherapy, despite a lack of virological response. These
include the COPILOT study comparing colchicine with low-
dose peginterferon alfa-2b [25,26], which showed both high
rates of premature discontinuation of therapy and that
maintenance therapy with peginterferon was associated
with improved disease free survival almost exclusively in
patients with portal hypertension, and the EPIC3 program
with peginterferon alfa-2b [27]. Recent results from the
HALT-C trial [28], which investigated the effect of treating
non-responders with peginterferon alfa-2a and RBV con-
cluded overall that long-term therapy with peginterferon did
not reduce the rate of disease progression and so do not
support maintenance therapy in patients with HCV and
advanced hepatic ﬁbrosis who are prior non-responders.
Interestingly, a signiﬁcant decline in clinical outcomes was
observed in patients with chronic HCV and advanced ﬁbrosis
or cirrhosis who achieved a profound decline in HCV RNA,
deﬁned as >4 log and⁄or undetectable with subsequent
breakthrough or relapse, suggesting that a small subgroup of
patients may beneﬁt [29]. Unless results of the ongoing
studies provide additional guidance, continued treatment of
patients cannot be recommended.
Recommendations for optimizing treatment in patients
with HCV genotype 1
Shorter treatment for patients with a rapid virological response
The current 48-week treatment duration, recommended for
HCV genotype 1-infected patients, may potentially result in
the over-treatment of some genotype 1-infected patients who
are more likely to achieve SVR, i.e. patients with low viral
load before treatment and rapid virological response (RVR)
Table 1 Detection limits and range of linear quantiﬁcation for HCV RNA tests [20]
Test
Detection limit
(cut-off) IU⁄mL
Dynamic range of linear
quantiﬁcation IU⁄mL
Lower limit Upper limit
Qualitative assays
Versant qualitative assay (Siemens, Eschborn, Germany) 5–10 NA NA
Cobas Amplicor v2.0 (Roche, Mannheim, Germany) 50 NA NA
Quantitative assays
Abbott Real Time 10 12 100 000 000
Cobas TaqMan real-time PCR assay (Roche) 10 43 69 000 000
Cobas Amplicor Monitor v2.0 (Roche) 600 600 500 000
Versant HCV RNA 3.0 (Bayer) 615 615 7700 000
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Treatment of chronic hepatitis C 77at week 4. Clearly it is desirable to expose patients to the
shortest possible treatment duration – without compromis-
ing efﬁcacy – in order to minimize the likelihood of adverse
events and reduce costs. Hadziyannis et al. found that more
than one third of individuals with HCV genotype 1 who were
randomized to 24 weeks of therapy with pegylated IFNa-2a
plus RBV achieved SVR [3]. Moreover, patients infected with
HCV genotype 1 who became HCV RNA-negative by week 4,
i.e. patients with RVR, were more likely to achieve SVR than
those who did not become HCV RNA negative until week 12
[22]. A recent prospective trial demonstrated that patients
with low baseline HCV RNA levels (£600 000 IU⁄mL) and
an RVR achieve an SVR rate of up to 90% (Fig. 2) [30].
Jensen et al. observed that almost a quarter (22.6%) of HCV
genotype 1 patients treated with peginterferon plus RBV
achieved RVR [31]. Of these patients, 89% showed SVR after
treatment duration of only 24 weeks. Both pegylated inter-
ferons have recently been approved in the EU for shortened
treatment duration of 24 weeks for HCV genotype 1 patients
with low-viral load (LVL) (deﬁned as <800 000 IU⁄mL
for peginterferon alfa-2a and <600 000 IU⁄mL for pegin-
terferon alfa-2b) and RVR [7,8]. To assure accurate deter-
mination of baseline viral load in cases with HCV RNA
concentrations between 400 000 and 1 million IU⁄mL,
physicians should consider performing two measurements
using the same technique, from samples taken at least
4 weeks apart. Whether 10 or 50 IU is the most appropriate
cut-off for determining RVR remains unclear, however, and is
under investigation. Recently, Sarrazin et al. compared clin-
ical outcomes for large cohorts of patients whose serum
samples were analysed using both the COBAS TaqMan
TM
(detection limit approximately 10 IU⁄mL) and COBAS Am-
plicor
TM (detection limit <50 IU⁄mL) assays. In this study,
RVR rates and subsequent SVR rates were similar when RVR
was deﬁned as undetectable of below 15 IU⁄mL by the CO-
BAS TaqMan assay in comparison with undetectable
(<50 IU⁄mL) by the COBAS Amplicor assay, implying that
HCV RNA levels rapidly decline not only to below 50 IU⁄mL
but also below 15 IU⁄mL in patients achieving an RVR [15].
Interestingly, relapse rates were consistently lower in pa-
tients with undetectable HCV RNA at week 4 by COBAS
TaqMan  compared with COBAS Amplicor , although the
full signiﬁcance of this remains to be established [15].
Patients should not be considered for shorter treatment
duration if they have a baseline viral load above 600–
800 000 IU⁄mL and⁄or have cirrhosis, are co-infected with
HIV, or are immunosuppressed. Other factors inﬂuencing
virological response that may also be considered include
metabolic syndrome, insulin resistance and extensive stea-
tosis. Zeuzem et al. demonstrated that the efﬁcacy of pegin-
terferon alfa-2a plus RBV is comparable between patients
with genotype 1 infection and persistently normal alanine-
aminotransferase (ALT) and those with elevated ALT levels
[32]. However, SVR rates were signiﬁcantly lower in those
patients with persistently normal ALT treated for 24 weeks
compared with 48 weeks (13% vs 40%, respectively), which
also suggests that such patients may not be suitable candi-
dates for shorter therapy. As this study of patients with
persistently normal ALT did not include evaluation of RVR,
it was not possible to identify a potential patient subgroup
within this population (e.g. low viral load and⁄or RVR) who
might beneﬁt from shorter treatment.
DETERMINING PRE-TREATMENT VIRAL LOADS
AND DEFINING LOW VS HIGH-VIRAL LOADS
The deﬁnition and differentiation between low and high viral
loads is still under discussion. Historically, pre-treatment
Fig. 2 Rapid virological response predicts
sustained virological response in HCV-1
infected patients with low baseline viral
load (£ 600 000 IU⁄mL).
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78 S. Zeuzem et al.viral load was classiﬁed as high or low using a cut-off of
2 · 10
6 copies⁄mL, based on data generated using con-
ventional interferon-based regimens or pegylated interferon
monotherapy [33,34]. When HCV RNA assays were stan-
dardized, conversion of copies⁄mL to IU⁄mL according to the
WHO standard gave varying results depending on the assay
used; 800 000 IU⁄mL has been recommended as the deci-
sion threshold for high versus low viraemia [35]. However,
recent data suggest that a baseline level of 400 000 IU⁄mL
is the most effective cut-off for a high or low probability to
achieve SVR in genotype 1-infected patients [36,37]. This
level was conﬁrmed in a large real-life experience study [38]
and in a further study by Martinot-Peignoux and colleagues,
with the caveat that it should be applied to treatment-naı ¨ve
patients only [39]. In a recent study, pre-treatment HCV-
RNA levels of 250 000 IU⁄mL best discriminated between
genotype 1-infected patients with or without SVR after
24 weeks of therapy in patients with low pre-treatment viral
load [37]. Whether a single cut-off level for pre-treatment
viraemia is sufﬁcient or whether several ranges of pre-
treatment HCV RNA levels might allow for individualized
treatment duration remains to be elucidated. Furthermore,
cut-offs for low or high baseline HCV RNA concentration
were established mainly on the basis of standard RT-PCR
and bDNA assays and re-deﬁnition by the currently used
real-time PCR-based assays is required. According to current
data, treatment duration of 24 weeks in genotype-1 infected
patients should be strongly considered for patients who
achieve RVR and have a baseline viral load below
800 000 IU⁄mL.
DETERMINING RVR AT WEEK 4
Patients who are considered for shortened treatment dura-
tion must be tested at week 4 for RVR (i.e. no HCV RNA
detectable) using a highly sensitive method (limit of detec-
tion £50 IU⁄mL) [15]. The week 4 value should be mea-
sured as close as possible to day 28 of therapy, i.e. between
the fourth and ﬁfth injection of peginterferon. Patients
without assessment of RVR should not be considered as
candidates for shortened therapy duration.
Monitoring is an important feature in the management of
CHC; not only to document treatment success, but also as an
indicator of compliance and adherence. Patients with RVR at
week 4 should be tested again at week 12 (±5 days).
The probability that the PCR test is negative at week 4 but
positive at week 12 is low; only 1 of 22 patients who
experienced virological breakthrough prior to week 24 had
an RVR [40].
Optimizing response by reducing relapse rates in patients
with HCV genotype 1
A patient with virological relapse is one who achieved an
end-of-treatment (EOT) response but who failed to achieve
an SVR. Relapse has been reported to occur at similar rates
for patients treated with peginterferon alfa-2a and -2b (18%
and 19%, respectively) who were treated for 48 weeks
according to the standard treatment algorithm [1,2]. The
IDEAL study, which investigates response to peginterferon
alfa-2a and two different doses of peginterferon alfa-2b with
RBV in patients with genotype 1 CHC, is also addressing this
issue [41]. Intensiﬁcation of treatment is a possible approach
to reduce the incidence of relapse. IDEAL is accepted as late-
breaker at EASL 2008.
INCREASED DOSE OF RIBAVIRIN
Recent studies suggest that high-dose RBV in combination
with pegylated interferon can improve response in genotype
1-infected patients. Lindahl et al. used an individualized
dosing regimen based largely on renal function, in an
attempt to achieve >15 lmol⁄L steady-state RBV concen-
tration in 10 treatment-naı ¨ve patients [42]. After initial dose
adjustments, the mean dose of RBV was 2540 mg, qd (range
1600–3600 mg, qd) and the mean RBV concentration
achieved was 14.7 lM (range 7.8–22.0 lm) at weeks
24–48. Nine of 10 patients achieved SVR following treat-
ment of up to 48 weeks duration, but with more frequent
and severe side effects, in particular anaemia. All patients
required erythropoietin at some time during treatment.
A recent study by Fried et al. demonstrated an improve-
ment in SVR in genotype 1-infected patients with body
weight >85 kg treated with a higher dose of RBV, especially
in conjunction with a higher dose of peginterferon [43].
Patients treated with 270 lg peginterferon alfa-2a and
1600 mg, qd, RBV showed an SVR of 47% compared with
28% in patients treated with the standard dosing regimen.
This improvement was driven mainly by a marked reduction
in relapse in the high-dose group compared with the
standard-dose group (19% vs 40%, respectively). However,
the use of a higher dose regimen was associated with an
increased rate of haematological adverse events. More
recently, in a prospective, open-label, randomized, controlled
pilot study comparing 48 weeks of treatment with pegin-
terferon plus standard weight-based RBV with or without
erythropoietin (groups 1 and 2), and peginterferon plus
higher weight-based RBV plus erythropoietin (group 3), SVR
was signiﬁcantly greater (P < 0.05) in group 3 patients
(49%) due to a signiﬁcant decline in relapse rate [44].
Overall, the results of these studies provide encouraging data
regarding the possibility of optimizing treatment regimens
for patients with more difﬁcult to treat disease.
EXTENDING TREATMENT DURATION FOR SLOW
VIROLOGICAL RESPONDERS
Evidence from three randomized clinical trials support the
case for extending treatment duration beyond 48 weeks in
HCV genotype 1 patients with a slow virological response,
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Treatment of chronic hepatitis C 79i.e. HCV RNA > 50 IU⁄mL at week 12 but undetectable
(<50 IU⁄mL) at week 24 [45–47]. Berg et al. randomized
patients to 48 or 72 weeks of treatment with peginterferon
alfa-2a (180 lg, qw) plus RBV (800 mg, qd) and analysed
the resulting SVR and relapse rates [45]. Extended treatment
of 72 weeks did not increase the SVR rate in the intent-
to-treat population; which suggests that it is inappropriate to
extend treatment for all genotype 1-infected patients. How-
ever, the study demonstrated that identifying patients with
and without virological response at week 12 using a sensi-
tive molecular test (50 IU⁄mL) could facilitate the decision
on therapy duration for each patient on an individual basis.
Patients who remained HCV RNA positive at week 12 had
signiﬁcantly higher SVR rates when treated for 72 rather
than 48 weeks (29% vs 17%; P = 0.04). The greatest beneﬁt
from extended treatment duration (72 weeks) was observed
in patients with detectable HCV RNA, but with levels below
6000 IU⁄mL, at week 12. The frequency and intensity of
adverse events was similar in the 48- and 72-week treat-
ment groups, suggesting that extended treatment can be
manageable in terms of tolerability. Sanchez-Tapias et al.
randomized patients without RVR (i.e., HCV
RNA > 50 IU⁄mL at week 4) to treatment with pegylated
interferon alfa-2a (180 lg, qw) and RBV (800 mg, qd) for
48 or 72 weeks [46]. Extending treatment to 72 weeks
signiﬁcantly increased the SVR rate compared with the
standard 48 weeks of therapy (45% vs 32%, respectively;
P = 0.01). In genotype 1-infected patients, this effect was
particularly evident, with 44% of patients who received
72 weeks of treatment achieving SVR compared with 28%
of patients who were treated for 48 weeks (P = 0.003).
The incidence of adverse events was similar between the
two groups, although treatment discontinuation was
signiﬁcantly more frequent in the 72-week group (36% vs
18%; P = 0.0004). A retrospective analysis of patients from
the European-based trials, including that of Berg et al.,
demonstrated that patients without RVR but achieving
subsequent early viral response (EVR) (>2 log10 HCV RNA
decrease), beneﬁted from extending treatment duration and
achieved a higher SVR rate (77% after 72 weeks vs 31%
after 48 weeks [48].
Pearlman et al. examined the effect of longer treatment
duration with pegylated interferon alfa-2b plus weight-
based RBV in patients infected with HCV genotype 1 who
met EVR criteria at week 12 (>2 log10 drop in baseline
HCV RNA), but who had detectable HCV RNA at week 12
and became HCV RNA-negative at week 24 [47]. This
group of slow viral responders was then treated for either
48 or 72 weeks. Results showed a 39% SVR in the
72-week arm compared with 18% SVR in the 48-week
arm; treatment extension did not seem to result in an in-
crease in dose reductions of RBV or discontinuations. Taken
together, the available data suggest that longer duration of
therapy improves sustained response rates in slow
virological responders.
Proportion of HCV genotype 1-infected patients who could
be considered for shortened or extended therapy duration
An extended treatment duration of 72 weeks can be con-
sidered in slow virological responders, deﬁned as patients
who are HCV RNA positive at week 12 but become unde-
tectable at week 24. These patients comprise approximately
20% of the HCV genotype 1-infected population, a not
insubstantial proportion [45]. Similarly, around 15% of all
HCV genotype-1 infected patients could beneﬁt from a
shorter treatment duration without compromising the SVR
rate; again constituting a clinically relevant proportion of
patients [30]. A summary of the recommendations for
optimizing treatment in patients with HCV genotype 1 is
given in Fig. 3.
GENOTYPES 2 AND 3
Interest has also focused on whether treatment duration
could be individualized in some patients with genotype 2 and
3 infection; i.e. shortened due to the overall high rate of SVR
(80%) achieved with the standard 24 weeks of treatment,
or prolonged in slow responders.
Recommendations for optimizing treatment in patients
with HCV genotypes 2 and 3
Shorter treatment for patients with a rapid virological response
A number of studies have investigated whether it might be
possible to reduce treatment duration in some patients
with chronic HCV genotypes 2 or 3 infection based on
RVR. Several small studies have demonstrated comparable
SVR rates after 16 weeks and 24 weeks treatment in
patients with either genotype 2 (Table 2) or 3 (Table 3)
infection who achieve an RVR [49–52]. However, in the
large-scale randomized, multinational ACCELERATE study,
in which a lower dose of RBV was used, overall SVR rates
were lower following 16 weeks of peginterferon plus RBV
compared with 24 weeks treatment in genotype 2 and 3
patients, although this difference only reached signiﬁcance
in genotype 2 patients [9]. Among the patients with an
RVR, SVR rates were signiﬁcantly higher in the 24-week
group than in the 16-week group, both overall (85% vs
79%, P < 0.001) and within each genotype group,
although patients who achieved an RVR were more likely
to achieve an SVR overall [9]. Overall, the signiﬁcant
difference seen in SVR rates was found to reﬂect a sig-
niﬁcantly higher relapse rate in the 16-week group (31%)
compared with the 24-week group (18%; P < 0.001);
shorter treatment duration was associated with a signiﬁ-
cantly higher risk of relapse in both genotype 2 and 3
patients [9].
There is some evidence to suggest that genotype 2 and 3
may respond differently to treatment; overall SVR rates tend
to be somewhat lower for genotype 3 patients who do not
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80 S. Zeuzem et al.achieve an RVR compared with genotype 2 patients who do
not achieve RVR, and also after shorter treatment duration
in patients who do achieve RVR [9,50,51,53,54]. Whether
genotype 3-infected individuals should not therefore be
considered for shorter duration therapy requires further
investigation.
Baseline HCV RNA levels also inﬂuence SVR rates and
patients with low pre-treatment serum HCV RNA levels and
RVR have been reported to respond equally well to both 16
and 24 weeks of therapy (SVR rates of 82–100% and 81–
100%, respectively) [9,49,50,53]. It is possible, therefore,
that these patients may be considered for shorter treatment
duration.
Genotype 2 and 3 infected patients with severe ﬁbrosis are
less likely to achieve either RVR or SVR, and to relapse more
frequently following 12–14 weeks of antiviral therapy
[9,49,51,53]. Andriulli et al. found that patients with low
pre-treatment ALT levels were also found to relapse more
frequently following shorter treatment duration (14% after
12–14 weeks vs 2% after 24 weeks; P = 0.04) [51]. These
ﬁndings suggest that patients with severe ﬁbrosis or normal
pre-treatment ALT levels are most likely unsuitable candi-
(a) 
(b)  Determine viral load prior  
to treatment 
Tw  o samples,  
4   we  eks apar  t 
Test for RVR at week 4 
Consider treating  
patients with RVR  
and LVL at baseline 
for 24 weeks
Plan to treat patients
without RVR for 48 weeks
Test for ETR at 
week 24 
Test for SVR at 
week 48 
Test for EVR at week 12 
If HCV RNA 
undetectable, 
continue treatment 
to 48 week  s 
If >2 log  10 re  duction  
in HCV RNA,  
consider treating for  
72 week  s 
If <2 log  10 
reduction, 
stop 
treatment 
Test for ETR at 
week 48 
Test for SVR at 
week 72 
If HCV RNA 
undetectable at 
week 24 consider 
treating for 72 week  s 
If HCV RNA 
detectable at week 
24, stop 
treatment 
Test for ETR at 
week 72 
Test for SVR at 
week 96 
Monitor 
Monitor 
Monitor 
Genotype   1 
Fig. 3 (a) Proposed treatment algorithm for patients with HCV genotype 1 based on response at weeks 4 (RVR), 12 (EVR) and
24. (b) Guidance for treatment and monitoring of response to peginterferon⁄RBV combination therapy in patients infected
with HCV genotype 1. EVR, early viral response; RVR, rapid viral response; SVR, sustained viral response; PCR, polymerase
chain reaction; ETR, end-of-treatment response.
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Treatment of chronic hepatitis C 81dates for short-term treatment, but prospective studies are
needed to conﬁrm these observations.
Optimizing response by reducing relapse rates in patients with
HCV genotypes 2 and 3
There is evidence that patients with HCV genotype 2 or 3
and higher baseline viral load have lower rates of SVR and
higher relapse rates after 24 weeks of treatment than those
with lower HCV RNA baseline levels [9,32,50,55], and that,
in patients without RVR, the lowest rates of relapse are
obtained with 48 weeks of treatment and a higher RBV dose
[11]. Whether increasing treatment duration would help
reduce relapse rates in patients with high baseline viral load
requires further evaluation.
Although patients with genotypes 2 and 3 are generally
considered to respond similarly to treatment, there is also
some evidence to suggest that genotype 3 patients have
lower SVR rates and subsequently higher relapse rates than
genotype 2 patients [32]. An analysis of data from the WIN-
R trial of peginterferon alfa-2b also demonstrated higher
Table 2 Overview of short-term treatment versus standard (24-week) treatment in patients (pts) with HCV genotype 2
infection
Ref
Duration
(weeks)
Ribavirin
dose
(mg⁄day)
SVR in pts
with RVR
following
shorter
duration
therapy (%)
SVR in pts
with RVR
following
standard
duration
therapy (%)
SVR in RVR-pts with
low vs high
baseline viraemia
following shorter
duration therapy
Relapse rate
following shorter
vs standard
duration in RVR-pts
54 14* 800–1400 91 N⁄A 92% vs 88%*
 10% vs N⁄A
50
 12* 1000–1200 87 89 N⁄A9 % vs N⁄A
51 16 800–1200 95 95 100% vs 93%*
§ N⁄A
53
 16 800–1400 100 98 No data 0% vs 2%
9
 16 800 78 85 No data No data
55 14* 800–1400 93 97 100% vs 90%** 7% vs 3%
*Included only patients with RVR.
Patients randomized before treatment.
HCV RNA £ 600 000 IU⁄mL vs >600 000 IU⁄mL.
§HCV RNA £ 800 000 IU⁄mL vs >800 000 IU⁄mL.
**HCV RNA £ 400 000 IU⁄mL vs > 400 000 IU⁄mL.
Table 3 Overview of short-term treatment versus standard (24-week) treatment in patients (pts) with HCV genotype 3
infection
Ref
Duration
(weeks)
Ribavirin
dose
(mg⁄day)
SVR in pts
with RVR
following
shorter
duration
therapy (%)
SVR in pts
with RVR
following
standard
duration
therapy (%)
SVR in RVR-pts
with low vs
high baseline
viraemia following
shorter duration
therapy
Relapse rate
following shorter
vs standard
duration in RVR-pts
54 14* 800–1400 89 N⁄A 98% vs 79%
 11% vs N⁄A
50 12* 1000–1200 77 100 N⁄A4 % vs N⁄A
51 16 800–1200 76 75 93% vs 54%*
§ N⁄A
9 16 800 80 85 No data No data
55 14 800–1400 84 92 80% vs 86%** 16% vs 8%
*Included only patients with RVR.
Patients randomized before treatment.
HCV RNA £ 600 000 IU⁄mL vs >600 000 IU⁄mL.
§HCV RNA £ 800 000 IU⁄mL vs >800 000 IU⁄mL.
**HCV RNA £ 400 000 IU⁄mL vs >40 000 IU⁄mL.
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82 S. Zeuzem et al.SVR rates and lower relapse rates in genotype 2 infected
patients compared with genotype 3 (72% vs 63%, and 5% vs
10%, respectively) [56]. It is possible that genotype 3-infected
patients would beneﬁt from longer treatment duration an-
d⁄or higher RBV dose compared with genotype 2-infected
patients; however current data supporting this comes pre-
dominantly from retrospective analyses and requires evalu-
ation in prospective clinical trials.
A recent study suggests that patients infected with geno-
type 3 who have cirrhosis are 10 times more likely to relapse
following treatment with conventional or peginterferon plus
RBV than those without cirrhosis [57], a ﬁnding consistent
with the results from the trial by Hadziyannis et al. and
described below [3]. If data from cirrhotic patients infected
with HCV genotype 1 are extrapolated to those with other
genotypes, it is likely that longer treatment duration may be
beneﬁcial in reducing relapse in genotype 2 and 3 patients
with cirrhosis. However, this remains to be established in
prospective clinical studies.
Proportion of HCV genotype 2 and 3-infected patients who could
be considered for shortened or extended therapy duration
In general, patients infected with HCV genotypes 2 or 3
should not be routinely treated for less than the currently
recommended 24 weeks to avoid an increased risk of viro-
logic relapse. However, patients with a low pre-treatment
viral load (£400 000 IU⁄mL) and an RVR (as determined by
a highly sensitive assay) have the highest probability of
achieving an SVR with 16 weeks of therapy (Fig. 4). Such a
regimen may be a reasonable option for these patients,
especially if tolerability of longer treatment may be a con-
cern. The cut-off for low-viral load in patients with geno-
types 2 and 3 based on the ACCELERATE data is
£400 000 IU⁄mL [9]. As with genotype 1, baseline viral
load should be determined in two samples, taken at least
4 weeks apart.
Shortening of treatment duration should not be consid-
ered for patients with cirrhosis, persistently normal ALT
values or co-infection with HBV or immunocompromised
patients such as those with HIV infection or those who have
undergone liver transplantation.
There may be patient subgroups with genotype 2 or 3
infection that might beneﬁt from extended treatment
duration to reduce relapse rates. Results from the trial by
Hadziyannis et al. found evidence for reduced relapse rates in
genotype 2 and 3 pts with advanced ﬁbrosis⁄cirrhosis as well
as high baseline viral load when treated for 48 weeks in
comparison with 24 weeks [3].
However, due to insufﬁcient data from prospective clinical
trials, there is currently not enough evidence for such rec-
ommendations. It is possible that a higher, weight-based
dose of RBV may balance the increased risk of relapse
associated with a shorter treatment duration, but this re-
mains to be proven. An overview of the proposed treatment
strategy for patients with genotypes 2 and 3 is given in
Fig. 5.
ADDITIONAL FACTORS TO CONSIDER
Consideration of ribavirin dose
RBV monotherapy does not induce a signiﬁcant antiviral
response in patients with CHC, but in combination with
interferon, RBV markedly improves ETR response, reduces
relapse rates and improves SVR rates. A number of
mechanisms including direct inhibition of RNA replication,
immunomodulation, inhibition of inosine monophosphate
dehydrogenase, and enhanced viral mutagenesis have been
proposed to explain the action of RBV in CHC as reviewed by
Dixit et al. but its overall mode of action remains to be fully
elucidated [58]. The main serious adverse event associated
with the use of RBV is dose-dependent haemolytic anaemia.
The optimal target dose for RBV is not well established.
A recent publication supports the individualization of RBV
dosing according to HCV genotype and bodyweight, and
highlights a number of clinical variables that inﬂuence the
Fig. 4 Overview of the ACCELERATE
data: 16 vs 24 weeks. SVR: sustained
viral response.
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Treatment of chronic hepatitis C 83likelihood of SVR in contrast to the occurrence of anaemia
[10]. The percentage of patients with SVR increased from
40% to 50% when RBV dose was increased from 12 to
16 mg⁄kg in patients with genotype 1 infection, but was
much less inﬂuenced by RBV dose in genotype 2 and 3
patients [10]. A higher apparent clearance of RBV, older age
and cirrhosis had a negative impact on achieving an SVR.
Gender and RBV dose⁄kg were the most important prog-
nostic factors for anaemia. However, as anaemia is not a
universal risk in all treated patients, the initial high dosing
strategy of 1000 or 1200 mg, qd, according to bodyweight
appears to be appropriate. For heavier patients, RBV doses
>1200 mg, qd, may be initiated as they are likely to be
associated with additional efﬁcacy and a manageable anae-
mia risk (provided that the dose does not greatly exceed
15 mg⁄kg⁄day) [10]. As discussed above, Lindahl et al.
demonstrated in a small pilot study that administration of
ultra high-dose RBV (ranging from 1600–3600 mg, qd) in
genotype 1 patients according to an individualized schedule
is feasible but is associated with more frequent and serious
side effects such as anaemia [42]. In this albeit small study,
nine of 10 patients achieved an SVR; however, two of 10
patients required blood transfusion for haemoglobin levels
<8.0 g⁄dL and all patients required treatment with eryth-
ropoietin (range 9000 to 30 000 IU⁄week) and oral iron
supplements. However, recommendations cannot be made
on observations made on such limited patient numbers.
Retrospective analyses of the original study by Hadzi-
yannis et al. showed that in patients without RVR, the
lowest rates of relapse were obtained with 48 weeks of
treatment and a higher RBV dose [11]. In contrast, treat-
ment duration and RBV dose did not inﬂuence SVR in
patients with RVR. For genotype 2 and 3 infected patients,
higher RBV doses do not improve SVR or relapse rate in
patients with RVR on the standard 800 mg, qd, dose [11].
However, for the minority of patients who do not achieve
RVR, it is possible that increased RBV dose may improve
treatment outcome, although sufﬁcient data are not yet
available to make a clear recommendation [11]. A study by
Ferenci et al. suggests that, in genotype 2 and 3 infected
patients treated with a standard ﬁxed dose of 800 mg, qd,
RBV, SVR was greater in patients who were exposed to the
highest mean dose of RBV based on body weight [59]. These
ﬁndings are consistent with a retrospective analysis of data
(a)
(b)
Fig. 5 (a) Proposed treatment algorithm for patients with HCV genotype 2 or 3 based on response at week 4 (RVR).
(b) Guidance for treatment and monitoring of response to peginterferon⁄RBV combination therapy in patients infected with
HCV genotypes 2 or 3. EVR, early viral response; RVR, rapid viral response; SVR, sustained viral response; PCR, polymerase
chain reaction; ETR, end-of-treatment response; LVL, low viral load; HVL, high viral load.
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theless, whether increasing RBV exposure in heavier
patients will improve SVR remains uncertain.
A number of studies have shown that erythropoietin can
be used to improve quality of life, maintain RBV dose and
subsequently improve adherence [60–62]. Although eryth-
ropoietin may have a role in the management of RBV-related
anaemia, a recent study by Shiffman et al. failed to show an
improvement in SVR in genotype 1-infected patients given
epoetin alpha at the initiation of therapy to maintain hae-
moglobin levels between 12 and 15 g⁄dL [9]. This was a
three arm, prospective, open-label, randomized, controlled
pilot study comparing 48 weeks of treatment with pegin-
terferon plus standard weight-based RBV with or without
erythropoietin (groups 1 and 2), and peginterferon plus
higher weight-based RBV plus erythropoietin (group 3).
A signiﬁcantly smaller percentage of group 2 patients had a
decline in haemoglobin to less than 10 g⁄dL (9% vs 34%;
P < 0.05) and required that the RBV dose be reduced (10%
vs 40%; P < 0.05) compared to group 1 patients. Despite
this, SVR was similar in these groups (19–29%). SVR was
signiﬁcantly greater (P < 0.05) in group 3 patients (49%)
due to a signiﬁcant decline in relapse rate (Table 4).
It has been suggested that the use of erythropoietin may
be an appropriate strategy for managing anaemia, improv-
ing quality of life and increasing adherence to therapy,
especially in patients with genotype 1 infection [63].
However, its use was not permitted in registration trials of
peginterferons and RBV and no recommendation for its use
in anaemia associated with RBV is included in the Summary
of Product Characteristics. Moreover, its addition to the
treatment regimen would be associated with additional
costs, inconvenience and potential side effects [64]. In con-
clusion, the limited data available concerning use of eryth-
ropoietin are insufﬁcient to make clear recommendations.
If shortening treatment below the standard duration is to
be considered, careful reassessment of RBV dose is neces-
sary, since RBV dose and treatment duration appear to be
closely linked. In a prospective Austrian study, reducing
the dose of RBV to 400 mg did not adversely affect the rate
of SVR compared with the standard 800 mg daily dose in
genotype 2 and 3 infected patients treated for 24 weeks
[65]. However, due to the limited data available, further
studies in RBV dose and treatment duration are warranted
before any recommendations can be made. In our opinion,
weight-based dosing of RBV is advantageous for genotype
1-infected patients, while its relevance for genotype 2 and
3 infected patients remains to be further elucidated,
particularly for shorter treatment duration and for patients
without RVR. Generally and independent of HCV genotype,
RBV dose is less important in patients with RVR and
becomes more and more important if only cEVR or slow
response is present. The higher percentage of patients with
genotype 2 and 3 achieving RVR in comparison with
genotype 1 explains the observed differences between
genotypes.
The inﬂuence of adherence⁄dose reduction on sustained virological
response
Both adherence and RBV dose have a major impact on SVR
rates. Patients who receive the optimal dose of peginterferon
and RBV for the planned duration have higher rates of SVR
than those who require dose reductions [21,66–68].
Adherence to therapy is important for treatment success,
especially in patients with genotype 1 infection who undergo
longer-term treatment, as there is evidence that extended
therapy may improve SVR in some patients. Adherence
during the initial treatment period is especially important, as
early viral suppression is a positive predictor of SVR.
Therefore, adherence during the early stages of treatment
may be more crucial than overall adherence [22].
Given these ﬁndings, physicians should discuss the
importance of adherence with patients before initiating
therapy. Education of patients, family members and care-
givers about potential side effects and their prospective
management is an integral aspect of treatment. Frequent
Table 4 Virologic response in patients treated for 48 weeks with standard or higher weight-based doses of ribavirin
PEG IFN a-2a + WBR PEG IFN a-2b + WBR + EPO PEG IFN a-2a + HWBR + EPO
ITT population (n)4 8 4 9 4 9
Mean RBV dose (mg⁄day) 1016 ± 170 1102 ± 174 1224 ± 175
Dose reduction (%) 40 10 31
RVR (%) 9 8 11
EVR (%) 68 65 63
VR at end of treatment (%) 46 31 53
SVR (%) 29 19 49
Relapse rate (%) 36 40 8
WBR, standard weight-based ribavirin (13.3 mg⁄kg⁄day); HDR, high-dose weight-based ribavirin (15.2 mg⁄kg⁄day); VR,
virological response (HCV RNA undetectable); RVR, rapid virological response (VR at 4 weeks); EVR, early virological response
(VR at 12 weeks).
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health and social functioning, as well as the clinical side
effects of HCV therapy, are important aspects of patient
management.
Therapidandeffectivemanagementofsideeffectsiscrucial
for treatment success, as adverse events such as anaemia,
negatively affect adherence. Identifying and addressing the
main side effects of HCV therapy can therefore improve
adherence to treatment and potentially allow optimal out-
comes to be achieved [69]. Dose reductions are used to man-
age adverse events encountered during therapy. A recent
retrospective study of 569 patients enrolled in phase III trials
of 48 weeks treatment with peginterferon alfa-2a and RBV,
showed that reductions in RBV (£97% cumulative dose) were
more frequent than those of peginterferon alfa-2a (43% vs
27%) [70]. Neither EVR nor SVR were affected adversely by
RBV reductions when the cumulative RBV exposure was
greater than 60%. However, SVR was reduced signiﬁcantly
(P = 0.0006) in patients with less than 60% cumulative RBV
dose. Currently, guidelines suggest that levels of RBV should
be reduced to 600 mg, qd, in cases of anaemia (<10 g⁄dL),
which could reduce cumulative RBV levels below the 60%
threshold in genotype 1 patients. It has been suggested that
more gradual incremental dose reductions of 200 mg may be
less likely to impact on SVR than the ad hoc reduction to
600 mg, particularly in patients infected with genotype 1
where RBV dose appears to have a greater impact on SVR
compared to other genotypes [10]. Prospective studies, how-
ever,wouldberequiredtoestablishmoreclearlytheimpactof
RBV dose reduction on SVR.
Re-treatment of patients
A major problem for physicians managing patients with CHC
is patients with an end-of-treatment virological response but
no SVR (relapsers) or patients with HCV RNA detectable at
end of treatment with current standard therapy (non-
responders). Re-treatment of relapsers is more likely to yield
favourable results than re-treatment of non-responders.
Re-treatment with peginterferon plus RBV has been inves-
tigated in patients who relapsed after interferon monother-
apy or interferon plus RBV therapy. Patients who have
relapsed following treatment with standard interferon-based
regimens often respond to re-treatment with peginterferon
plus RBV. In these patients, SVR rates of 41–59% have been
reported. Response to re-treatment is most likely in
non-genotype 1 patients, patients with mild or moderate
ﬁbrosis, and patients with low viral load at baseline [71–77].
Peginterferon plus RBV re-treatment should therefore be
considered for all patients who have previously responded to
a conventional interferon-based regimen and subsequently
relapsed.
Treatment failure can be related to tolerability problems
and subsequent discontinuation. It is conceivable that
patients non-responsive to one form of peginterferon may be
more responsive to treatment with the other form of pegin-
terferon.Furthermore,additionaleffortstomanagesideeffects
in patients retreated with peginterferon plus RBV may im-
proveadherenceandsoimprovechancesofachievinganSVR.
Treatment failure is associated with a higher long-term
mortality [78]. Data suggest that selected patients who fail to
achieve SVR may beneﬁt from re-treatment with peginter-
feron-based regimens; however, rates of SVR following
re-treatment are far lower than those achieved in treatment-
naı ¨ve patients. Overall, SVR rates of 4–26% have been
reported, with patients who failed to respond to standard IFN
monotherapy being most likely to respond to re-treatment
with peginterferon plus RBV [71–76,79,80]. Following the
results of the ongoing EPIC-3 trial, peginterferon alfa-2b
in combination with RBV was recently approved for the
re-treatment of relapsers or non-responders to a prior course
of interferon alfa (pegylated or non-pegylated) with RBV. In
this trial, 1336 patients with moderate to severe ﬁbrosis who
failed previous interferon-based treatment received pegin-
terferon alfa-2b plus RBV for up to 48 weeks and were fol-
lowed for a further 24 weeks. 23% achieved SVR. The
authors found a strong correlation between achieving SVR
and achieving a cEVR with undetectable HCV RNA levels at
week 12 of treatment [81]. In the REPEAT study, which
investigated the effects of intensiﬁed treatment with higher
ﬁxed-dose induction of peginterferon and⁄or longer treat-
ment duration in previous non-responders to peginterferon
alfa-2b plus RBV, re-treatment with ﬁxed-dose induction and
longer duration provided the highest SVR rates and the
lowest relapse rates [82].
While some patients are classiﬁed as virological relaps-
ers⁄non-responders, they may have a biochemical response
– i.e. reduction or normalization of ALT. Preliminary re-
sults from the HALT-C trial showed that peginterferon alfa-
2a maintenance therapy led to improvements in ALT level,
HCV viral load and necroinﬂammation. Despite this how-
ever, long term maintenance therapy did not show any
effect on the rate of disease progression [28]. These ﬁnd-
ings were in accordance with a long-term study of pegin-
terferon alfa-2b in non-responders which found no
difference in the rate of serious long-term liver
complications including decompensation and hepatocellu-
lar carcinoma despite improvements in ﬁbrosis [83]. In the
long-term COPILOT study comparing colchine with
low-dose peginterferon alfa-2b, improved disease free
survival associated with peginterferon alfa-2b maintenance
therapy occurred almost exclusively in patients with portal
hypertension [26]. Given these data, the role of long-term,
continuous therapy with peginterferon (or RBV or both) for
non-responders cannot be generally recommended.
In summary, decisions regarding re-treatment should
include consideration of the severity of the underlying liver
disease, adherence⁄compliance and tolerance issues, the
previous therapy and type of response to it, viral genotype
and other predictive factors for response [4].
  2008 The Authors
Journal compilation   2008 Blackwell Publishing Ltd
86 S. Zeuzem et al.CONCLUSION
In conclusion, recent research suggests a number of poten-
tial approaches for optimizing therapy for patients with CHC
and, as a consequence, increasing SVR rates. Here we have
attempted to analyse these ﬁndings and translate them into
practical advice, to help practitioners make evidence-based
treatment decisions in everyday clinical practice. We have
also highlighted areas where currently available data do not
provide conclusive evidence to suggest amending treatment
approaches at present. There is potential for further indi-
vidualization of therapy when such data become available.
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